...
首页> 外文期刊>American Journal of Nephrology >Arginine and asymmetric dimethylarginine in puromycin aminonucleoside-induced chronic kidney disease in the rat.
【24h】

Arginine and asymmetric dimethylarginine in puromycin aminonucleoside-induced chronic kidney disease in the rat.

机译:嘌呤霉素氨基核苷诱导的大鼠慢性肾脏疾病中的精氨酸和不对称二甲基精氨酸。

获取原文
获取原文并翻译 | 示例

摘要

Background/Aims: Reduced renal L-arginine (L-Arg) synthesis/transport, induction of arginases and increased endogenous NOS inhibitor, asymmetric dimethylarginine (ADMA) will inhibit NO production. This study investigated pathways of L-Arg synthesis/uptake/utilization, ADMA degradation and oxidant/antioxidants in puromycin aminonucleoside (PAN) chronic kidney disease (CKD). Methods: Rats were given low- (LD) or high-dose (HD) PAN and followed for 11 weeks for proteinuria. BP was measured and blood and tissues were harvested and analyzed for abundance of argininosuccinate synthase (ASS) and lyase (ASL), arginase, cationic amino acid transporter (CAT1) and dimethylargininedimethylaminohydrolase (DDAH) in kidney, cortex, aorta and liver. Arginase and DDAH activity, plasma L-Arg and ADMA, renal pathology and creatinine clearances were also measured. Results: PAN caused dose-dependent kidney damage and hypertension and creatinine clearance fell in HD-PAN. Renal ASS fell in HD-PAN, renal cortex and aortic ASL and membrane CAT1 fell in both PAN groups. There was no activation of renal arginase, but aortic arginase increased in LD-PAN. Renal DDAH activity fell moderately in LD-PAN and markedly in HD-PAN where hepatic DDAH activity also fell. Plasma L-Arg was unchanged while ADMA rose moderately and dose-dependently with PAN. There were several indices of oxidative stress which was most prominent in HD-PAN. Conclusion: Reduction in renal ASS/ASL and loss of renal cortex CAT1 compromises renal L-Arg synthesis and release. Loss of aortic CAT1 impairs L-Arg uptake. Increased plasma ADMA was associated with progressive loss of renal DDAH activity. However, loss of renal clearance and falls in hepatic DDAH activity in HD-PAN did not have additive effects on plasma ADMA.
机译:背景/目的:减少肾脏L-精氨酸(L-Arg)的合成/转运,诱导精氨酸酶和增加内源性NOS抑制剂,不对称二甲基精氨酸(ADMA)将抑制NO的产生。这项研究调查了嘌呤霉素氨基核苷(PAN)慢性肾脏病(CKD)中L-Arg合成/摄取/利用,ADMA降解以及氧化剂/抗氧化剂的途径。方法:给大鼠给予低(LD)或高剂量(HD)PAN,然后进行11周蛋白尿治疗。测量血压并采集血液和组织,并分析肾脏,皮质,主动脉和肝脏中的精氨琥珀酸合酶(ASS)和裂解酶(ASL),精氨酸酶,阳离子氨基酸转运蛋白(CAT1)和二甲基精氨酸二甲基氨基水解酶(DDAH)的丰度。还测量了精氨酸酶和DDAH活性,血浆L-Arg和ADMA,肾病理学和肌酐清除率。结果:HD-PAN引起PAN剂量依赖性肾脏损害,高血压和肌酐清除率下降。在两个PAN组中,HD PAN中的肾ASS下降,肾皮质和主动脉ASL和膜CAT1下降。肾脏精氨酸酶没有激活,但LD-PAN中的主动脉精氨酸酶增加。 LD-PAN的肾脏DDAH活性适度下降,HD-PAN的肝脏DDAH活性也明显下降。血浆L-Arg保持不变,而PAN的ADMA呈中等剂量依赖性。在HD-PAN中,氧化应激的几个指标最为突出。结论:肾ASS / ASL的降低和肾皮质CAT1的丧失会损害肾脏L-Arg的合成和释放。主动脉CAT1的丧失会损害L-Arg的摄取。血浆ADMA升高与肾脏DDAH活性的逐步丧失有关。然而,HD-PAN中肾清除率的丧失和肝DDAH活性的下降对血浆ADMA没有累加作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号